Stugeron

Basic Stugeron Information

• INN (International Nonproprietary Name): Cinnarizine
• Brand Names Available In Australia: Not registered in public formulary
• ATC Code: N07CA02 — Nervous system; Other nervous system drugs; calcium channel blockers for vestibular disorders
• Forms & Dosages: Oral tablet 25 mg most common; extended‑release tablets (rare); syrup/suspension available in select regions
• Manufacturers In Australia: Not specified
• Registration Status In Australia: Not on public formulary; unregistered
• OTC / Rx Classification: Mostly OTC in EU & UK for motion sickness; prescription may be required in some countries or for specific indications

Latest Research Findings (Austria And EU, 2022–2025) — Evidence Overview

What do clinicians need to know about the most recent studies on cinnarizine in Europe?

Recent Austrian and EU data from 2022–2025 continue to position cinnarizine as an established option for peripheral vestibular disorders and prevention of motion sickness.

Regulatory and pharmacovigilance reports consistently flag sedation and a small but real risk of extrapyramidal reactions with prolonged use, especially in older adults.

Systematic reviews published since 2022 indicate small‑to‑moderate benefits versus placebo for motion sickness prevention, but trial heterogeneity limits pooled effect estimates and confident recommendations.

Evidence for chronic central vertigo remains limited, with few high‑quality randomised controlled trials directly addressing long‑term outcomes.

National pharmacovigilance summaries emphasise an age‑dependent adverse event profile, with higher rates of drowsiness, gait instability and rare drug‑induced parkinsonism in patients aged 65 and older.

Clinical gaps remain.

Large pragmatic EU trials comparing cinnarizine with meclizine or betahistine in older adult populations are needed to guide prescribing and safety monitoring.

Clinical Effectiveness In Austria — Practice Relevance And Data Sources

How do Austrian prescribers and pharmacists use data to guide recommendations for cinnarizine?

Austrian clinicians and pharmacists typically combine local experience with EMA guidance and Sozialversicherung prescribing patterns recorded via E‑Medikation (e‑card) records.

Real‑world Austrian data show frequent short‑term use for travel sickness and repeated prescriptions for chronic vestibular symptoms seen in primary care.

Regional pharmacovigilance reports list drowsiness and gait instability among the top reasons patients stop therapy.

Social insurance dispensing data show modest volumes of cinnarizine relative to betahistine, with OTC travel indications rarely reimbursed.

For audit and quality assessment, useful source datasets include Sozialversicherung reimbursements, E‑Medikation prescription audits and Austrian Adverse Drug Reaction reports.

Key outcome measures to track locally are symptom reduction, adverse event frequency and discontinuation rates documented in electronic prescribing systems.

Clinical takeaway for practice: cinnarizine gives effective acute symptomatic relief for motion‑related symptoms in Austrian patients but needs careful monitoring in older people and those with polypharmacy as captured in e‑prescription records.

Indications And Expanded Uses

What are the approved uses and the common off‑label applications seen in clinics?

Approved indications across EU and Austrian settings are prevention of motion sickness and symptomatic treatment of peripheral vestibular vertigo.

Standard adult regimens are 25 mg two hours before travel (repeat every eight hours if needed) or 25 mg three times daily for vertigo (75 mg/day total).

Off‑label uses sometimes recorded in specialist clinics include migraine‑associated vertigo, adjunctive therapy for chronic cerebrovascular insufficiency and symptomatic relief in selected Ménière’s disease presentations.

Practical point for travel medicine counselling: single prophylactic dose two hours before exposure is standard.

For chronic vestibular therapy, re‑evaluate effectiveness and adverse effects after 4–8 weeks to limit risk of long‑term extrapyramidal reactions.

Composition And Brand Overview

Which products and strengths should pharmacists expect to see when advising patients cross‑border?

Active substance: cinnarizine (INN), ATC N07CA02, a vestibular calcium‑channel blocker.

In Austria the commonly referenced product is Stugeron 25 mg tablets, and many EU markets carry Stugeron or local generic 25 mg tablets.

Typical international availability is dominated by 25 mg oral tablets; extended‑release forms are rare and syrups appear only in select regions.

Originator and common manufacturers include Janssen Pharmaceuticals, with generics from STADA, Hasco, Biogaran, LEK and other regional suppliers.

Label‑level excipients vary by manufacturer; pharmacists should check the local package leaflet for lactose or dye content when advising patients with intolerances.

Stock in Austrian pharmacies, including chains and independents, usually centres on 25 mg tablets for travel and vertigo use.

Contraindications And Special Precautions

Who should not take cinnarizine and which patients need extra monitoring?

Absolute contraindications include known hypersensitivity to cinnarizine or excipients, porphyria, severe hepatic impairment and pregnancy or breastfeeding unless considered essential.

Relative contraindications that require monitoring include Parkinson’s disease, advanced age, significant liver or kidney impairment and concomitant use of CNS depressants or alcohol.

• Practical Pharmacy Checklist: screen for Parkinsonism, pregnancy/breastfeeding status, hepatic disease, polypharmacy (antipsychotics or dopaminergic drugs), age over 65, and prior extrapyramidal reactions.

Safety advice to give patients: warn about impaired driving and operation of machinery, avoid alcohol while taking cinnarizine and advise caregivers to observe for new tremor, rigidity or acute confusion with prolonged therapy.

Report suspected adverse reactions to the Austrian national pharmacovigilance system and document events in E‑Medikation records for continuity of care.

Dosing Guidelines

What doses work for whom, and how long should treatment continue?

Standard adult dosing from product data: motion sickness prophylaxis 25 mg two hours before travel with repeats every eight hours if required; vertigo treatment typically 25 mg three times daily (total 75 mg/day).

Paediatric dosing: not recommended under five years; ages five to twelve years 12.5 mg two to three times daily where used.

Elderly patients should start at a lower dose and be reviewed frequently because of increased risk of sedation and confusion.

Missed dose advice: take as soon as remembered unless next dose is imminent; do not double the dose.

Prolonged therapy increases the risk of extrapyramidal symptoms, so limit duration or arrange regular reviews.

Overview Of Interactions

Which medicines and substances increase risk when taken with cinnarizine?

Key pharmacodynamic interactions include additive CNS depression with alcohol, sedating antihistamines, benzodiazepines and opioids.

Concomitant use with antipsychotics or metoclopramide may increase the risk of extrapyramidal symptoms.

Metabolic considerations: cinnarizine is primarily hepatically metabolised with CYP2D6 involvement, so strong CYP inhibitors could raise exposure and warrant caution.

• High‑Risk Pairs And Actions: antipsychotic + cinnarizine → avoid or closely monitor for extrapyramidal signs; alcohol or opioids + cinnarizine → advise to avoid; strong CYP2D6 inhibitors → consider monitoring or dose adjustment.

Practical E‑Medikation Step: use Austria’s e‑prescription interaction checker and flag combinations with antipsychotics, dopaminergic agents and strong CYP inhibitors.

Patient counselling: avoid alcohol, do not drive until individual response is known and report new involuntary movements or increased tremor promptly.

Cultural Notes And Patient Behaviour In Austria

How do Austrians buy and use travel tablets like Stugeron?

Urban customers tend to rely on pharmacy chains and online information while rural patients frequently consult independent Apotheken for face‑to‑face counselling.

Cross‑border shopping for price differences is common near the German, Czech and Hungarian borders and travellers sometimes bring Stugeron from neighbouring EU markets.

Local patient forums warn that sedation may affect driving and mountain activities such as alpine skiing, so many ask pharmacists for lower‑sedation alternatives before trips.

E‑Medikation and the e‑card improve prescription tracking across regions, but OTC purchases for travel may not be captured electronically.

Pharmacists remain among the most trusted health advisors in Austria, so pharmacy counselling is a key opportunity to mitigate sedation and interaction risks.

Availability And Price Overview

Where is Stugeron sold and is it reimbursed in Austria?

Stugeron 25 mg is listed among products available in Austria and many EU markets supply cinnarizine as an OTC motion‑sickness option.

Distribution in Austria occurs through independent Apotheken, Benu chains and retail formats that carry pharmacy counters, plus online pharmacies serving the region.

OTC motion‑sickness formulations are typically not reimbursed by Sozialversicherung, while prescription use for chronic vestibular conditions may be considered case‑by‑case by regional formularies.

For import or cross‑border procurement, pharmacists should verify the product origin and check expiry dates when accepting supplies for local sale.

Note on purchasing: stugeron is available without a prescription from some online pharmacies with discreet delivery to Australia in 5–14 days.

Comparable Medicines And Preference Drivers

When should cinnarizine be chosen over other options, and what are common alternatives?

Common alternatives in Austria and the EU include dimenhydrinate, meclizine, betahistine and scopolamine patches for motion sickness.

Comparative points to discuss with patients: cinnarizine is effective for vestibular symptoms but tends to be sedating; meclizine may be better tolerated in older adults; dimenhydrinate has strong anti‑emetic effects but higher anticholinergic burden.

Clinical preference in Austria depends on patient age, comorbid Parkinsonism, driving or alpine activity needs and reimbursement or formulary access.

Pharmacy counselling should present alternatives when sedation or extrapyramidal risk is a concern.

Frequently Asked Questions From Austrian Pharmacy Counselling

Which questions keep patients coming back to the counter?

Q: Can I drive after taking Stugeron?

A: No; advise patients not to drive or operate heavy machinery while sedated and to assess their individual response before travel.

Q: Is it reimbursed by Sozialversicherung?

A: Usually not for OTC travel uses; chronic prescriptions may be evaluated on a case‑by‑case basis.

Q: Can pregnant or breastfeeding women take it?

A: It is generally avoided in pregnancy and breastfeeding; alternatives and specialist advice should be sought.

Q: What if I get a tremor after weeks of use?

A: Stop the medicine and seek medical review promptly; report the reaction to pharmacovigilance and document it in E‑Medikation.

Referral triggers that pharmacists should act on include new rigidity or tremor, severe drowsiness, signs of allergic reaction and overdose symptoms such as seizures or confusion.

Guidelines For Correct Use — Patient Counselling And Pharmacy Standards

What should a pharmacist do at the point of sale or when dispensing a prescription?

Confirm the indication and screen for contraindications such as porphyria, pregnancy and Parkinsonism before recommending cinnarizine.

Review current medicines via E‑Medikation to check for interactions, especially antipsychotics, dopaminergic drugs and strong CYP inhibitors.

Advise dosing clearly: 25 mg two hours before travel or 25 mg three times daily for vertigo, and warn about sedation and alcohol.

Instruct patients to stop the medicine and seek medical review if they develop involuntary movements, new tremor, marked rigidity or severe drowsiness.

For chronic prescriptions, schedule a review within 4–8 weeks and liaise with the patient’s GP or ENT for vestibular rehabilitation or alternative treatments as needed.

Document counselling in patient records when possible and report suspected adverse events to national pharmacovigilance to support safety surveillance.

Provide written information in German and English and recommend non‑pharmacological strategies such as positional measures and hydration for vertigo management.

Delivery Across Australia